Inzy stock forecast.

Find the latest Cano Health, Inc. (CANO) stock quote, history, news and other vital information to help you with your stock trading and investing.Inozyme Pharma, Inc. Common Stock (INZY) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.Stocks Rankings for INZY. U.S. News compares companies to their industry peers based on a variety of company fundamentals, performance metrics and investor preferences to help you find the right ...Heading out for an outdoor adventure? Whether you’re planning a picnic, a hiking trip, or a beach day, one essential tool you need in your arsenal is a detailed weather 10 day forecast.Dec 1, 2023 · Website. 2015. 56. Doug Treco. https://www.inozyme.com. Inozyme Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases in the United States. The company’s lead product candidate is INZ-701, a soluble, recombinant, genetically ...

Aug 9, 2023 · For the current quarter, INZY is expected to report an EPS forecast of -$0.45. In terms of annual financials, INZY reported an annual revenue of $0.00 for the last year and an annual profit of -$67.1 million. INZY Stock Shows Promising Performance on August 9, 2023: Optimistic Price Forecasts and Unanimous Buy Rating. INZY stock, belonging to ...

Oct 13, 2023 · Incyte stock price predictions for 2023, 2024, 2025, 2026, 2027 using artificial intelligence. How much will Incyte cost in 2021-2025?

The Price and Consensus chart displays the company's stock price along with the consensus estimate. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The ...INZY | stock. $3.85. 0.00%. $228 M. 0.00%. $0.00-Overview - INZY. Overview. Ratings. Recommendation. Payouts. Div Growth. Capture Strategy. News & Research. Profile. Home Dividend Stocks Health Care Biotech Pharma Large Pharma INOZYME PHARMA, INC. (INZY) Dividend Data Stock Data Avg Price Recovery N/A.Dec 2, 2023 · The consensus price target of analysts on Wall Street is $21.00, which implies an increase of 81.67% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $15.00 and $40.00 respectively. As a result, INZY is trading at a discount of -938.96% off the target high and -289.61% off the low. 4 Wall Street research analysts have issued 12 month price targets for Argo Blockchain's stock. Their ARBK share price targets range from $1.45 to $2.75. On average, they expect the company's stock price to reach $2.23 in the next twelve months. This suggests a possible upside of 90.9% from the stock's current price.

Find the latest Inozyme Pharma, Inc. INZY analyst stock forecast, price target, and recommendation trends with in-depth analysis from research reports. Date Range. …

Incyte Corp is in the bottom half of stocks based on the fundamental outlook for the stock and an analysis of the stock's chart. A rank of 43 means that 57% of stocks appear more favorable to our system. Who this matters to: Overall Ranking is a comprehensive evaluation. It considers technical and fundamental factors and is a good starting ...

Advanced Charting News Inozyme Pharma Inc. No significant news for in the past two years. Key Stock Data P/E Ratio (TTM) N/A EPS (TTM) $-1.58 Market Cap $189.51 M …Find the latest MEI Pharma, Inc. (MEIP) stock quote, history, news and other vital information to help you with your stock trading and investing.Inozyme Pharma (INZY) Stock Forecast and Price Target 2023 S&P 500 4,559.34 DOW 35,390.15 QQQ 389.51 12 crew members are missing, 1 dead after a …24 Wall Street research analysts have issued 1 year target prices for Walt Disney's shares. Their DIS share price targets range from $76.00 to $136.00. On average, they expect the company's stock price to reach $108.95 in the next twelve months. This suggests a possible upside of 14.5% from the stock's current price.As the old saying goes, “Forewarned is forearmed.” This sentiment holds true when it comes to weather forecasting as well. One of the primary advantages of a 30-day extended weather forecast is the ability to plan ahead with confidence.

Earnings for Inozyme Pharma are expected to decrease in the coming year, from ($1.34) to ($1.35) per share. Inozyme Pharma has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, March 27th, 2024 based off prior year's report dates. Read More.Dec 1, 2023 · View Inozyme Pharma, Inc INZY investment & stock information. Get the latest Inozyme Pharma, Inc INZY detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. Forecast . Price target. 21.00 0.00 0.00%. The 6 analysts offering 1 year price forecasts for INZY have a max estimate of — and a min estimate of —. Analyst rating. Based on 7 analysts giving stock ratings to INZY in the past 3 months. EPS. Annual Annual Quarterly Quarterly More MoreLululemon stock has had its run. On Monday, Ike Boruchow downgraded the athletic apparel company to “equal weight”. His $445 price objective is roughly in line …ARQT | Complete Arcutis Biotherapeutics Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.Dec 1, 2023 · Analyst Forecast According to 16 analysts, the average rating for INCY stock is "Buy." The 12-month stock price forecast is $79.25, which is an increase of 46.71% from the latest price.

Inozyme Pharma (INZY) Stock Forecast and Price Target 2023 S&P 500 4,559.34 DOW 35,390.15 QQQ 389.51 12 crew members are missing, 1 dead after a …Nov 20, 2023 · The weighted average target price per Incyte share in Dec 2023 is: 52.02. In Dec, the Positive dynamics for Momo shares will prevail with possible monthly volatility of 3.880% volatility is expected. Pessimistic target level: 51.04. Optimistic target level: 53.10. Incyte stock price predictions for 2023 using artificial intelligence.

Find the latest Inozyme Pharma, Inc. INZY analyst stock forecast, price target, and recommendation trends with in-depth analysis from research reports. Date Range. …Stock Price Forecast. The 15 analysts offering 12-month price forecasts for Paycom Software Inc have a median target of 190.00, with a high estimate of 270.00 and a low estimate of 140.00. The ...The company’s stock had a trading volume of 1,882,507 shares, compared to its average volume of 1,653,219. The company’s fifty day simple moving average is $55.35 and its 200-day simple moving ...Weather forecasts play an essential role in our daily lives, helping us plan our activities and stay prepared for any weather conditions that may come our way. One of the most common types of forecasts is the 7-day weather forecast, which p...Find the latest Troika Media Group, Inc. (TRKA) stock quote, history, news and other vital information to help you with your stock trading and investing.Inozyme Pharma Inc Registered Shs Stock , INZY. 3.70 0.00 0.00% After-market 04:02:05 PM NAS. Start Trading. Add to watchlist. Plus500. 81% of retail CFD accounts lose ...Incyte Corp is in the bottom half of stocks based on the fundamental outlook for the stock and an analysis of the stock's chart. A rank of 43 means that 57% of stocks appear more favorable to our system. Who this matters to: Overall Ranking is a comprehensive evaluation. It considers technical and fundamental factors and is a good starting ...

Inozyme Pharma, Inc. Common Stock (INZY) Nasdaq Listed. DATA AS OF Nov 10, 2021 10:17 AM ET. 0. Add to Watchlist. Add to Portfolio. INZY INZY HISTORICAL DATA.

Oct 27, 2023 · Analyzing the anticipated performance of Incyte, the ceiling value that the stock is expected to reach in 2024 stands at a promising $63.82.Indicating a bullish trend, an upside potential of 12.32% signals profitable prospects, with an average monthly return of 0.88%, beckoning investors to consider amplifying their portfolios.

Turning to the calls side of the option chain, the call contract at the $57.50 strike price has a current bid of 65 cents. If an investor was to purchase shares of INCY stock at the current price ...Find the latest Avenue Therapeutics, Inc. (ATXI) stock quote, history, news and other vital information to help you with your stock trading and investing.Oct 27, 2023 · Analyzing the anticipated performance of Incyte, the ceiling value that the stock is expected to reach in 2025 stands at a promising $79.7.Indicating a bullish trend, an upside potential of 40.27% signals profitable prospects, with an average monthly return of 1.55%, beckoning investors to consider amplifying their portfolios. 2022 forecast According to management , Jakafi's 2022 sales will be at $2.3-2.4 billion, implying 10% year-on-year growth. Jakafi's gross-to-net adjustment is expected at 21%.See the latest Incyte Corp stock price (INCY:XNAS), related news, valuation, dividends and more to help you make your investing decisions.Mar 23, 2023 · Analyst Price Forecast Suggests 489.65% Upside As of March 24, 2023, the average one-year price target for Inozyme Pharma is $19.46. The forecasts range from a low of $4.54 to a high of $42.00. Nov 24, 2023 · The Incyte Corporation stock price gained 0.637% on the last trading day (Friday, 24th Nov 2023), rising from $53.40 to $53.74. During the last trading day the stock fluctuated 1.08% from a day low at $53.21 to a day high of $53.78. The price has risen in 7 of the last 10 days and is up by 2.32% over the past 2 weeks. Open $1.8900. Day Range 1.8200 - 1.9297. 52 Week Range 0.5800 - 6.7700. Market Cap $296.38M. Shares Outstanding 156.82M. Public Float 46.42M. Beta 0.48. Rev. per Employee $238.76K. P/E Ratio N/A.The Incyte Corp. stock forecast for tomorrow is $ 53.83, which would represent a 0.02% gain compared to the current price. In the next week, the price of INCY is expected to increase by 4.07% and hit $ 56.01. As far as the long-term Incyte Corp. stock forecast is concerned, here’s what our predictions are currently suggesting. Nov 20, 2023 · The weighted average target price per Incyte share in Dec 2023 is: 52.02. In Dec, the Positive dynamics for Momo shares will prevail with possible monthly volatility of 3.880% volatility is expected. Pessimistic target level: 51.04. Optimistic target level: 53.10. Incyte stock price predictions for 2023 using artificial intelligence.

Chart of the Day: Deckers Outdoor - Big Breakout Barchart - Wed Nov 8, 7:00AM CST. The Chart of the Day belongs to the casual footwear company Deckers Outdoors (DECK) . I found the stock by using Barchart's powerful screening functions to find stocks with the highest technical buy... DECK : 620.51 (+0.82%) Chart of the Day: …In fact, when combining a Zacks Rank #3 or better and a positive Earnings ESP, stocks produced a positive surprise 70% of the time, while they also saw 28.3% annual returns on average, according ...Turning to the calls side of the option chain, the call contract at the $57.50 strike price has a current bid of 65 cents. If an investor was to purchase shares of INCY stock at the current price ...Instagram:https://instagram. plug sharesnyse ddd financialsotcmkts cbdds and p 500 heat map Find the latest Kintara Therapeutics, Inc. (KTRA) stock quote, history, news and other vital information to help you with your stock trading and investing.Nov 29, 2023 · See the latest Inozyme Pharma Inc Ordinary Shares stock price (INZY:XNAS), related news, valuation, dividends and more to help you make your investing decisions. get apple idaok etf According to the SEC filings submitted on Wednesday and Thursday, Hopfner has raised his stake at Inozyme ( INZY) to 3.2M shares after buying ~207.8K and ~344.5K company stock at $4.05 and $4.54 ... advance auto parts vs autozone The 16 Wall Street analysts offering INCYTE CORP stock forecast in the last 6 months have average price target of $78.88 with a high forecast of $98.0 and a low forecast of $63.0. The average INCYTE CORP stock forecast represents a 46.78% increase from the last price of $53.7400016784668.Inozyme Pharma, Inc. Common Stock (INZY) After-Hours Stock Quotes - Nasdaq offers after-hours quotes and extended trading activity data for US and global markets.